دورية أكاديمية
Increased ACE2 Levels and Mortality Risk of Patients With COVID-19 on Proton Pump Inhibitor Therapy.
| العنوان: | Increased ACE2 Levels and Mortality Risk of Patients With COVID-19 on Proton Pump Inhibitor Therapy. |
|---|---|
| المؤلفون: | Liu JJ; Division of Gastroenterology and Hepatology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.; Current affiliation: Morehouse School of Medicine, Atlanta, Georgia, USA., Sloan ME; Division of Gastroenterology, University of Mississippi Medical Center (UMMC), Jackson, Mississippi, USA., Owings AH; Division of Gastroenterology, University of Mississippi Medical Center (UMMC), Jackson, Mississippi, USA., Figgins E; Department of Oral Immunology and Infectious Diseases, University of Louisville School of Dentistry, Louisville, Kentucky, USA., Gauthier J; Division of Gastroenterology, Department of Medicine, University of Florida, Gainesville, Florida, USA., Gharaibeh R; Division of Gastroenterology, Department of Medicine, University of Florida, Gainesville, Florida, USA., Robinson T; Division of Gastroenterology, University of Mississippi Medical Center (UMMC), Jackson, Mississippi, USA., Williams H; Division of Gastroenterology, University of Mississippi Medical Center (UMMC), Jackson, Mississippi, USA., Sindel CB; Division of Gastroenterology, University of Mississippi Medical Center (UMMC), Jackson, Mississippi, USA., Backus F; UMMC Center for Informatics and Analytics, Jackson, Mississippi, USA., Ayyalasomayajula K; UMMC Center for Informatics and Analytics, Jackson, Mississippi, USA., Parker A; Division of Gastroenterology, University of Mississippi Medical Center (UMMC), Jackson, Mississippi, USA., Senitko M; Division of Pulmonary, Critical Care, and Sleep Medicine, UMMC, Jackson, Mississippi, USA., Abraham GE 3rd; Division of Pulmonary, Critical Care, and Sleep Medicine, UMMC, Jackson, Mississippi, USA., Claggett B; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA., Horwitz BH; Boston Children's Hospital, Boston, Massachusetts, USA., Jobin C; Division of Gastroenterology, Department of Medicine, University of Florida, Gainesville, Florida, USA., Adelman RM; Department of Sociology, University at Buffalo, SUNY Buffalo, New York, New York, USA., Diamond G; Department of Oral Immunology and Infectious Diseases, University of Louisville School of Dentistry, Louisville, Kentucky, USA., Glover SC; Division of Gastroenterology, University of Mississippi Medical Center (UMMC), Jackson, Mississippi, USA. |
| المصدر: | The American journal of gastroenterology [Am J Gastroenterol] 2021 Aug 01; Vol. 116 (8), pp. 1638-1645. |
| نوع المنشور: | Journal Article; Multicenter Study |
| اللغة: | English |
| بيانات الدورية: | Publisher: Wolters Kluwer Health Country of Publication: United States NLM ID: 0421030 Publication Model: Print Cited Medium: Internet ISSN: 1572-0241 (Electronic) Linking ISSN: 00029270 NLM ISO Abbreviation: Am J Gastroenterol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: <2019-> : [Philadelphia, PA] : Wolters Kluwer Health Original Publication: New York, Elsevier Science, -2003. |
| مواضيع طبية MeSH: | Angiotensin-Converting Enzyme 2/*blood , COVID-19/*blood , COVID-19/*mortality , Proton Pump Inhibitors/*adverse effects, Adult ; Aged ; Female ; Humans ; Male ; Middle Aged ; Prospective Studies ; Retrospective Studies ; Risk Assessment |
| مستخلص: | Introduction: Proton pump inhibitor (PPI) use was recently reported to be associated with increased severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and worse clinical outcomes. The underlying mechanism(s) for this association are unclear. Methods: We performed a prospective study of hospitalized coronavirus disease 2019 (COVID-19) patients and COVID-negative controls to understand how PPI use may affect angiotensin-converting enzyme 2 (ACE2) expression and stool SARS-CoV-2 RNA. Analysis of a retrospective cohort of hospitalized patients with COVID-19 from March 15, 2020 to August 15, 2020 in 6 hospitals was performed to evaluate the association of PPI use and mortality. Covariates with clinical relevance to COVID-19 outcomes were included to determine predictors of in-hospital mortality. Results: Control PPI users had higher salivary ACE2 mRNA levels than nonusers, 2.39 ± 1.15 vs 1.22 ± 0.92 (P = 0.02), respectively. Salivary ACE2 levels and stool SARS-CoV-2 RNA detection rates were comparable between users and nonusers of PPI. In 694 hospitalized patients with COVID-19 (age = 58 years, 46% men, and 65% black), mortality rate in PPI users and nonusers was 30% (68/227) vs 12.1% (53/439), respectively. Predictors of mortality by logistic regression were PPI use (adjusted odds ratio [aOR] = 2.72, P < 0.001), age (aOR = 1.66 per decade, P < 0.001), race (aOR = 3.03, P = 0.002), cancer (aOR = 2.22, P = 0.008), and diabetes (aOR = 1.95, P = 0.003). The PPI-associated mortality risk was higher in black patients (aOR = 4.16, 95% confidence interval: 2.28-7.59) than others (aOR = 1.62, 95% confidence interval: 0.82-3.19, P = 0.04 for interaction). Discussion: COVID-negative PPI users had higher salivary ACE2 expression. PPI use was associated with increased mortality risk in patients with COVID-19, particularly African Americans. (Copyright © 2021 by The American College of Gastroenterology.) |
| التعليقات: | Comment in: Am J Gastroenterol. 2021 Oct 1;116(10):2153. (PMID: 34397446) Comment in: Am J Gastroenterol. 2021 Dec 1;116(12):2474. (PMID: 34459468) Comment in: Am J Gastroenterol. 2021 Dec 1;116(12):2474-2475. (PMID: 34515670) |
| References: | Price-Haywood EG, Burton J, Fort D, et al. Hospitalization and mortality among Black patients and White patients with Covid-19. N Engl J Med 2020;382:2534–43. Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: Prospective cohort study. BMJ 2020;369:m1966. Anderson MR, Geleris J, Anderson DR, et al. Body mass index and risk for intubation or death in SARS-CoV-2 infection: A retrospective cohort study. Ann Intern Med 2020;173:782–90. Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: Retrospective study. BMJ 2020;368:m1091. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020;323:1239–42. Lee LYW, Cazier JB, Starkey T, et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: A prospective cohort study. Lancet 2020;395:1919–26. Yancy CW. COVID-19 and African Americans. JAMA 2020;323:1891–2. Abrams EM, Szefler SJ. COVID-19 and the impact of social determinants of health. Lancet Respir Med 2020;8:659–61. Lipsitch M, Swerdlow DL, Finelli L. Defining the epidemiology of covid-19—Studies needed. N Engl J Med 2020;382:1194–6. Kantor ED, Rehm CD, Haas JS, et al. Trends in prescription drug use among adults in the United States from 1999–2012. JAMA 2015;314:1818–31. Rotman SR, Bishop TF. Proton pump inhibitor use in the U.S. ambulatory setting, 2002–2009. PLoS One 2013;8:e56060. Herzig SJ, Howell MD, Ngo LH, et al. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA 2009;301:2120–8. Othman F, Crooks CJ, Card TR. Community acquired pneumonia incidence before and after proton pump inhibitor prescription: Population based study. BMJ 2016;355:i5813. Zirk-Sadowski J, Masoli JA, Delgado J, et al. Proton-pump inhibitors and long-term risk of community-acquired pneumonia in older adults. J Am Geriatr Soc 2018;66:1332–8. Antoniou T, Macdonald EM, Hollands S, et al. Proton pump inhibitors and the risk of acute kidney injury in older patients: A population-based cohort study. CMAJ Open 2015;3:E166–71. Lazarus B, Chen Y, Wilson FP, et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med 2016;176:238–46. Bell JS, Strandberg TE, Teramura-Gronblad M, et al. Use of proton pump inhibitors and mortality among institutionalized older people. Arch Intern Med 2010;170:1604–5. Xie Y, Bowe B, Yan Y, et al. Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: Cohort study. BMJ 2019;365:l1580. Moayyedi P, Eikelboom JW, Bosch J, et al. Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin. Gastroenterology 2019;157:682–91.e2. Almario CV, Chey WD, Spiegel BMR. Increased risk of COVID-19 among users of proton pump inhibitors. Am J Gastroenterol 2020;115:1707–15. Luxenburger H, Sturm L, Biever P, et al. Treatment with proton pump inhibitors increases the risk of secondary infections and ARDS in hospitalized patients with COVID-19: Coincidence or underestimated risk factor? J Intern Med 2021;289:121–4. Lee SW, Ha EK, Yeniova AO, et al. Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: A nationwide cohort study with propensity score matching. Gut 2021;70:76–84. Freedberg DE, Conigliaro J, Wang TC, et al. Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: A propensity score matched retrospective cohort study. Gastroenterology 2020;159:1129–31.e3. Garg M, Royce SG, Tikellis C, et al. Imbalance of the renin-angiotensin system may contribute to inflammation and fibrosis in IBD: A novel therapeutic target? Gut 2020;69:841–51. Kuba K, Imai Y, Rao S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med 2005;11:875–9. Zang R, Gomez Castro MF, McCune BT, et al. TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes. Sci Immunol 2020;5:eabc3582. Ding S, Liang TJ. Is SARS-CoV-2 also an enteric pathogen with potential fecal-oral transmission? A COVID-19 virological and clinical review. Gastroenterology 2020;159:53–61. Cheung KS, Hung IFN, Chan PPY, et al. Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from a Hong Kong cohort: Systematic review and meta-analysis. Gastroenterology 2020;159:81–95. Lamers MM, Beumer J, van der Vaart J, et al. SARS-CoV-2 productively infects human gut enterocytes. Science 2020;369:50–4. Leung WK, To KF, Chan PK, et al. Enteric involvement of severe acute respiratory syndrome-associated coronavirus infection. Gastroenterology 2003;125:1011–7. Richter JE, Rubenstein JH. Presentation and epidemiology of gastroesophageal reflux disease. Gastroenterology 2018;154:267–76. Spechler SJ, Hunter JG, Jones KM, et al. Randomized trial of medical versus surgical treatment for refractory heartburn. N Engl J Med 2019;381:1513–23. Baldwin-Hunter BL, Knotts RM, Leeds SD, et al. Use of the electronic health record to target patients for non-endoscopic Barrett's esophagus screening. Dig Dis Sci 2019;64:3463–70. Moayyedi P, Eikelboom JW, Bosch J, et al. Pantoprazole to prevent gastroduodenal events in patients receiving rivaroxaban and/or aspirin in a randomized, double-blind, placebo-controlled trial. Gastroenterology 2019;157:403–12.e5. |
| المشرفين على المادة: | 0 (Proton Pump Inhibitors) EC 3.4.17.23 (Angiotensin-Converting Enzyme 2) |
| تواريخ الأحداث: | Date Created: 20210528 Date Completed: 20211027 Latest Revision: 20230718 |
| رمز التحديث: | 20240628 |
| DOI: | 10.14309/ajg.0000000000001311 |
| PMID: | 34047305 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1572-0241 |
|---|---|
| DOI: | 10.14309/ajg.0000000000001311 |